Fractalkine activates a signal transduction pathway similar to p2y12 and is associated with impaired clopidogrel responsiveness

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 8, 2012, Pages 1832-1840

  Flierl, Ulrike ^a   Fraccarollo, Daniela ^a   Lausenmeyer, Eva ^c   Rosenstock, Tim ^c   Schulz, Christian ^b   Massberg, Steffen ^b   Bauersachs, Johann ^a   Schäfer, Andreas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

fractalkine; G protein coupled receptors; P2Y12; thienopyridines

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; FRACTALKINE; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E1; PURINERGIC P2Y12 RECEPTOR; SERINE; VASODILATOR STIMULATED PHOSPHOPROTEIN;

AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DESENSITIZATION; DRUG EFFECT; DRUG RESPONSE; ENZYME ACTIVATION; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; LONG TERM CARE; MALE; PLATELET REACTIVITY INDEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; ALPROSTADIL; CHEMOKINE CX3CL1; CORONARY ARTERY DISEASE; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; SIGNAL TRANSDUCTION; TICLOPIDINE;

EID: 84864279058     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.250720     Document Type: Article

References (50)

1. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res. 2005;96:612-616. (Pubitemid 40478327)
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
3. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res. 2004;95:858-866. (Pubitemid 39435000)
4. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610-621. (Pubitemid 43209108)
5. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640-644.
6. Harrison JK, Jiang Y, Wees EA, Salafranca MN, Liang HX, Feng L, Belardinelli L. Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. J Leukoc Biol. 1999; 66:937-944. (Pubitemid 30010518)
7. Umehara H, Bloom E, Okazaki T, Domae N, Imai T. Fractalkine and vascular injury. Trends Immunol. 2001;22:602-607.
8. Damås JK, Boullier A, Waehre T, Smith C, Sandberg WJ, Green S, Aukrust P, Quehenberger O. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol. 2005;25:2567-2572. (Pubitemid 43732280)
9. Greaves DR, Häkkinen T, Lucas AD, Liddiard K, Jones E, Quinn CM, Senaratne J, Green FR, Tyson K, Boyle J, Shanahan C, Weissberg PL, Gordon S, Ylä-Hertualla S. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus-and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2001;21:923-929. (Pubitemid 34168647)
10. Schäfer A, Schulz C, Eigenthaler M, Fraccarollo D, Kobsar A, Gawaz M, Ertl G, Walter U, Bauersachs J. Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood. 2004;103:407-412. (Pubitemid 38140067)
11. Schulz C, Schäfer A, Stolla M, Kerstan S, Lorenz M, von Brühl ML, Schiemann M, Bauersachs J, Gloe T, Busch DH, Gawaz M, Massberg S. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation. 2007;116:764-773. (Pubitemid 47255994)
12. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329-1339.
13. Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost. 2007;5 Suppl 1:230-237. (Pubitemid 46958838)
14. Geiger J, Brich J, Hönig-Liedl P, Eigenthaler M, Schanzenbächer P, Herbert JM, Walter U. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol. 1999;19:2007-2011. (Pubitemid 29379936)
15. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244-2247. (Pubitemid 44497506)
16. Lau WC, Gurbel PA. Antiplatelet drug resistance and drug-drug interactions: role of cytochrome P450 3A4. Pharm Res. 2006;23:2691-2708. (Pubitemid 44885360)
17. Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, Herdeg C, Gawaz M. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost. 2008;6:54-61.
18. Schäfer A, Schöpp C, Flierl U, Schulz C, Leutke M, Massberg S, Bauersachs J. Increased vascular fractalkine expression and enhanced platelet reactivity to fractalkine in type-II diabetic ZDF-rats. Arterioscler Thromb Vasc Biol. 2006;26:P88.
19. Kikuchi Y, Imakiire T, Hyodo T, Kushiyama T, Higashi K, Hyodo N, Suzuki S, Miura S. Advanced glycation end-product induces fractalkine gene upregulation in normal rat glomeruli. Nephrol Dial Transplant. 2005;20:2690-2696. (Pubitemid 41672267)
20. Husberg C, Nygård S, Finsen AV, Damås JK, Frigessi A, Oie E, Waehre A, Gullestad L, Aukrust P, Yndestad A, Christensen G. Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure. J Mol Cell Cardiol. 2008;45:261-269.
21. Koziolek MJ, Müller GA, Zapf A, Patschan D, Schmid H, Cohen CD, Koschnick S, Vasko R, Bramlage C, Strutz F. Role of CX3C-chemokine CX3C-L/fractalkine expression in a model of slowly progressive renal failure. Nephrol Dial Transplant. 2010;25:684-698.
22. Schäfer A, Weinberger S, Flierl U, Eigenthaler M, Störk S, Walter U, Ertl G, Bauersachs J. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thromb Haemost. 2008;100:618-625.
23. Grossmann R, Sokolova O, Schnurr A, Bonz A, Porsche C, Obergfell A, Lengenfelder B, Walter U, Eigenthaler M. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost. 2004;92:1201-1206. (Pubitemid 39642526)
24. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38:1514-1521.
25. Garcia A, Kim S, Bhavaraju K, Schoenwaelder SM, Kunapuli SP. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. Biochem J. 2010;429:369-377.
26. Schoenwaelder SM, Ono A, Nesbitt WS, Lim J, Jarman K, Jackson SP. Phosphoinositide 3-kinase p110 beta regulates integrin alpha IIb beta 3 avidity and the cellular transmission of contractile forces. J Biol Chem. 2010;285:2886-2896.
27. Schoenwaelder SM, Ono A, Sturgeon S, Chan SM, Mangin P, Maxwell MJ, Turnbull S, Mulchandani M, Anderson K, Kauffenstein G, Rewcastle GW, Kendall J, Gachet C, Salem HH, Jackson SP. Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin alpha IIb beta 3 adhesive function in platelets. J Biol Chem. 2007;282:28648-28658. (Pubitemid 47606062)
28. Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F, Barragan P, Camoin-Jau L. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost. 2007;5:1630-1636. (Pubitemid 47091403)
29. Blindt R, Stellbrink K, de Taeye A, Müller R, Kiefer P, Yagmur E, Weber C, Kelm M, Hoffmann R. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost. 2007;98:1329-1334. (Pubitemid 350239106)
30. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol. 2006;46:277-300. (Pubitemid 43271191)
31. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol. 2005;46:1827-1832. (Pubitemid 41579803)
32. Wenaweser P, Hess O. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol. 2005;46:CS5-CS6.
33. Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, Stellos K, May AE, Gawaz M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006;27:2420-2425. (Pubitemid 44522148)
34. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA. 1998;95:8070-8074. (Pubitemid 28326067)
35. Chirkov YY, Chirkova LP, Sage RE, Horowitz JD. Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP-elevating effects of prostaglandin E1. J Cardiovasc Pharmacol. 1995;25:961-966.
36. Willoughby SR, Stewart S, Holmes AS, Chirkov YY, Horowitz JD. Platelet nitric oxide responsiveness: a novel prognostic marker in acute coronary syndromes. Arterioscler Thromb Vasc Biol. 2005;25:2661-2666. (Pubitemid 43732294)
37. Chirkov YY, Holmes AS, Willoughby SR, Stewart S, Wuttke RD, Sage PR, Horowitz JD. Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J Am Coll Cardiol. 2001;37:1851-1857. (Pubitemid 32499970)
38. Davis CN, Harrison JK. Proline 326 in the C terminus of murine CX3CR1 prevents G-protein and phosphatidylinositol 3-kinase-dependent stimulation of Akt and extrACEllular signal-regulated kinase in Chinese hamster ovary cells. J Pharmacol Exp Ther. 2006;316:356-363. (Pubitemid 41832615)
39. Lauro C, Catalano M, Trettel F, Mainiero F, Ciotti MT, Eusebi F, Limatola C. The chemokine CX3CL1 reduces migration and increases adhesion of neurons with mechanisms dependent on the beta1 integrin subunit. J Immunol. 2006;177:7599-7606. (Pubitemid 44846274)
40. Lyons A, Lynch AM, Downer EJ, Hanley R, O'Sullivan JB, Smith A, Lynch MA. Fractalkine-induced activation of the phosphatidylinositol-3 kinase pathway attentuates microglial activation in vivo and in vitro. J Neurochem. 2009;110:1547-1556.
41. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem. 2004;279:4186-4195. (Pubitemid 38199005)
42. O'toole A, Moule SK, Lockyer PJ, Halestrap AP. Tumour necrosis factor-alpha activation of protein kinase B in WEHI-164 cells is accompanied by increased phosphorylation of Ser473, but not Thr308. Biochem J. 2001;359(Pt 1):119-127. (Pubitemid 32939213)
43. Vincent EE, Elder DJ, Thomas EC, Phillips L, Morgan C, Pawade J, Sohail M, May MT, Hetzel MR, Tavaré JM. Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br J Cancer. 2011;104:1755-1761.
44. Schäfer A, Schulz C, Fraccarollo D, Schöpp C, Pfrang J, Ertl G, Massberg S, Bauersachs J. The CX3C chemokine fractalkine enhances vascular dysfunction and aggravates platelet activation in rats with chronic heart failure. J Heart Dis. 2008;6:29.
45. Kikuchi Y, Ikee R, Hemmi N, Hyodo N, Saigusa T, Namikoshi T, Yamada M, Suzuki S, Miura S. Fractalkine and its receptor, CX3CR1, upregulation in streptozotocin-induced diabetic kidneys. Nephron Exp Nephrol. 2004;97:e17-e25.
46. Dragomir E, Manduteanu I, Calin M, Gan AM, Stan D, Koenen RR, Weber C, Simionescu M. High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells. Thromb Haemost. 2008;100:1155-1165.
47. Koziolek MJ, Vasko R, Bramlage C, Müller GA, Strutz F. The CX(3) C-chemokine fractalkine in kidney diseases. Mini Rev Med Chem. 2009;9:1215-1228.
48. Jackson CE, Dalzell JR, Hogg KJ. Epinephrine treatment of anaphylaxis: an extraordinary case of very late acute stent thrombosis. Circ Cardiovasc Interv. 2009;2:79-81.
49. Nakamura T, Ariyoshi H, Kambayashi J, Ikeda M, Kawasaki T, Sakon M, Monden M. Effect of low concentration of epinephrine on human platelet aggregation analyzed by particle counting method and confocal microscopy. J Lab Clin Med. 1997;130:262-270. (Pubitemid 27451523)
50. Gear AR, Suttitanamongkol S, Viisoreanu D, Polanowska-Grabowska RK, Raha S, Camerini D. Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function. Blood. 2001;97:937-945. (Pubitemid 32154277)